Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAVO101 in moderate to severe atopic dermatitis
NCT06176040Phase 2Active, not recruiting
- Sponsor
- Tavotek Biotherapeutics
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of Tavo101 in atopic dermatitis (AD), sponsored by Tavotek Biotherapeutics. Started Mar 2024; status: active, not recruiting.
02
Drugs
Tavo101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06176040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176040.